Status:
COMPLETED
Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy
Lead Sponsor:
Beth Israel Medical Center
Collaborating Sponsors:
Riverside Research Institute
Conditions:
Clinical Stage T2b or Less of Prostate Cancer
Prostate Brachytherapy
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
In standard treatment, the seeds are placed throughout the prostate to treat the entire prostate. This is done because it was impossible to know where the cancer was located within the prostate. A new...
Detailed Description
Prostate brachytherapy is an increasingly popular treatment for clinically localized prostate cancer.In properly selected patients, it is highly effective with biochemical (PSA) disease free survival ...
Eligibility Criteria
Inclusion
- Clinical stage ≤ T2b according to the American Joint Commission on Cancer 6th Edition28
- PSA ≤ 10 ng/ml
- Gleason sum on biopsy ≤ 6
- Prostate volume ≤ 50 cc
- Willing to continue follow-up for at least two years.
Exclusion
- No prior hormone therapy
- No prior radiotherapy
- No history of collagen vascular disease
- No history of inflammatory bowel disease
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01227642
Start Date
February 1 2007
End Date
August 1 2014
Last Update
March 14 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St.Luke's-Roosevelt Hospital Center
New York, New York, United States, 10019